Supernus Pharmaceuticals, Inc. has reported impressive financial results for the third quarter of 2026, highlighting a strong performance that includes record revenues and significant growth in its product lines. The company is also on the brink of a merger with Indivior Pharmaceuticals, which is expected to close on November 2, 2026.

On October 29, 2026, Supernus announced total revenues of $226.8 million for the third quarter, representing an 18% increase compared to the same period last year. This growth is attributed to the robust performance of its four key products, which generated combined revenues of $192.2 million, a 29% increase year-over-year. The strong sales were driven primarily by the success of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO.

Background

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company is categorized under the SIC code 2834, which pertains to Pharmaceutical Preparations. Supernus has been actively filing reports with the SEC, with its most recent filings including several 8-K forms throughout October 2026.

What the Filing Says

According to the filing, "Supernus issued a press release regarding its financial results for the third quarter ended September 30, 2026." The filing also mentions that the company is hosting a conference call to discuss these results further.

Impact

The strong financial results and upcoming merger may significantly impact various stakeholders, including investors, employees, and healthcare providers. The merger with Indivior is expected to create a more diversified company that can serve a broader patient base, potentially enhancing long-term shareholder value.

What's Next

The filing indicates that Supernus is preparing for the merger with Indivior Pharmaceuticals, which is expected to close on November 2, 2026. Further details regarding the integration of the two companies may be disclosed in future filings.